Collects immune cells from people with HIV before and during antiretroviral treatment
Studies immune cells from adults with HIV, before and during early antiretroviral treatment.
Key facts
- Who runs it
- National Institute of Allergy and Infectious Diseases (NIAID)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
- Status
- Recruiting
- People taking part
- 750 people, planned
- Started
- 12 Jul 2002
- Type of study
- Observational, 2 groups
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with HIV-1 who have not yet started antiretroviral treatment. They give blood cells by leukapheresis for research.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Early (recent) or chronic HIV-1 infection, confirmed by HIV tests.
- Earlier treatment
- No antiretroviral medicine in the last six months, or only up to 4 weeks of recent use if it does not affect the study.
- Biomarker or test result
- Positive HIV antibody test and a positive confirmatory HIV test. In suspected early infection, HIV-1 RNA above 2,000 copies/ml may be used.
Main reasons for not taking part
- Pregnant or breastfeeding
- Current alcohol or drug abuse that could affect safety or following the study
- Poor venous access for blood collection
- Low blood counts (hemoglobin below 9.0 g/dL, hematocrit below 28 percent, platelets below 50,000)
- Blood pressure of 180/100 or higher
The registry criteria, word for word
Show all 4 criteriaShow less
Who cannot take part
- Be currently abusing alcohol or other drugs that potentially could interfere with the participant s compliance or safety
- Have a condition which in the opinion of the investigators would make the participant ineligible for the study
- Pregnant and / or breastfeeding
Other criteria
- INCLUSION CRITERIA:; Adult (18 years old or older) with HIV-1; Adequate venous access for research blood collection; Positive HIV antibody immunoassay and a positive confirmatory HIV test (as defined by current CDC criteria). Tests may be done in our clinic or by an outside provider. For individuals with suspected early HIV-1, the following additional criteria may be used: HIV-1 RNA levels of >2,000 copies/ml with a negative result from an HIV antibody immunoassay; Willingness to be able to make follow up visits at least once in the next 4 months and prior to the initiation of antiretroviral therapy (ART); Blood pressure < 180/100; pulse rate between 50-100 unless a lower pulse rate is considered normal for the volunteer; Adequate blood counts (hemoglobin greater than or equal to 9.0 g/dL, hematocrit greater than or equal to 28 percent, platelets greaterhan or equal to 50,000); Willingness and ability to give informed consent including consent for the storage of blood samples and genetic testing; Antiretroviral naive, no antiretroviral use in the last six months, or previously enrolled 02-I-0202 participants on whom there are samples stored in the repository; Participants who acquire HIV-1 while taking ART for pre-exposure prophylaxis will be eligible for enrollment as long as they meet diagnostic criteria for HIV positivity; Participants who enroll under another LIR apheresis protocol within the past three months and complete the apheresis within 4 weeks of starting ART will also be eligible for enrollment; Participants with limited (no more than 4 weeks before screening visit) recent use of ART may be eligible for study participation if, the opinion of the investigator, the ART usage will not impact the scientific validity of the protocol
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 120 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Kathleen R GittensTaking people
About the trial
What the trial wants to find out
There is evidence that early and aggressive treatment with antiretroviral drugs can prevent the loss of immune cell function that accompanies HIV infection. This study will use leukapheresis (drawing blood, separating out the white cells and returning the blood to the patient) to obtain blood cells from HIV-infected patients in either the acute or chronic stage of infection who are being treated with early highly active antiretroviral therapy (HAART). Leukapheresis is necessary to obtain enough cells to delineate the response of B cells to CD4+ T cell help, the CD8 factors associated with suppression of viral replication and normalization of immune function, and natural killer function relative to HIV disease.
Read full original descriptionShow less
Study participants will be adult (older than 18 years) HIV primary or acutely affected patients (those with a history of exposure to HIV but not yet showing chronic symptoms of HIV disease) and HIV chronically infected patients (those infected with HIV for longer than 12 months or showing other symptoms of HIV disease) who are not receiving HAART at the beginning of the study. The study seeks to enroll 30 primary and 30 chronic patients. Pregnant women will not be enrolled in the study; women who become pregnant will be dropped from the study.
Leukapheresis will be performed on each patient before HAART therapy begins and then three times a year. Each session will take between 1 and 3 hours.
This longitudinal study will enable researchers to examine the function of certain B cells, natural killer cells, and CD8+ T cells in people who do not have chronic HIV disease and in those who do have the disease and are treated with HAART.
...
The 2 groups in the trial
- HIV chronic infection
For example, an individual infected with HIV-1 for an indeterminate amount of time.
- HIV early infection
For example, a negative HIV antibody immunoassay within 6 months of a positive HIV antibody assay and confirmatory test (as defined by current CDC criteria).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
- Plain-language title
- Collects immune cells from people with HIV before and during antiretroviral treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT00039689, who can take part
- Record updated
- 10 November 2026